Moxonidine in Patients Undergoing Vascular Surgery
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Oct 25, 2005
Trial Information
Current as of April 25, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • abdominal aortic or peripheral vascular surgery
- Exclusion Criteria:
- • unstable angina,
- • severe symptomatic heart failure (NYHA IV)
- • systolic blood pressure at rest \< 100 mmHg
- • bradycardia (\<50/min)
- • higher grade AV heart block
- • creatinine clearance \< 30 ml/min
- • pregnancy
- • no consent
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Ch, Switzerland
Patients applied
Trial Officials
Miodrag Filipovic, PD Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials